MG
LVACU

Michael Gelband’s LAVA Medtech Acquisition Corp. Unit LVACU Stock Holding History

Michael Gelband’s Portfolio LVACU Stock Details LVACU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-50,000
Closed -$524K – 2893
2021
Q4 		$524K Buy
+50,000
New +$506K 0.01% 1367

Other funds holding LVACU

CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $469M AUM 32.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
CIM
Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
CM
Cohanzick Management Pleasantville, New York $231K AUM 3.17% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return

Michael Gelband's LVACU Position: Q1 2022 in Review

Michael Gelband sold out of LAVA Medtech Acquisition Corp. Unit (LVACU) in Q1 2022, closing a stake of 50,000 shares — an estimated $524K sold.

Michael Gelband first reported a position in LVACU in Q4 2021 and held it in 1 quarter. The position peaked at $524K in Q4 2021. 17 funds tracked by Wall St. Rank hold LVACU as of Q1 2022.

  • Michael Gelband reported no remaining LAVA Medtech Acquisition Corp. Unit position as of Q1 2022 after selling out during the quarter.
  • Michael Gelband sold 50,000 LAVA Medtech Acquisition Corp. Unit shares in Q1 2022, an estimated $524K.
  • Michael Gelband first reported a position in LAVA Medtech Acquisition Corp. Unit in Q4 2021 and held it in 1 quarter.
  • Michael Gelband's LAVA Medtech Acquisition Corp. Unit position peaked at $524K in Q4 2021.
  • 17 funds tracked by Wall St. Rank held LAVA Medtech Acquisition Corp. Unit as of Q1 2022.

Based on ExodusPoint Capital Management's 13F filing for Q1 2022, filed 13 May 2022.